AUAUniversity

Controversies, Confusion, and the Future of Urologic Post-Operative Opioid Prescribing Reduction Strategies

CME Available: https://auau.auanet.org/node/35160

Course Director: Jennifer Robles, MD, MPH

Faculty: Chad Brummett, MD; Gregory Auffenberg, MD, MS; Hitya Abraham, MD; Kevan Sternberg, MD

After participating in this activity, learners will be able to:

1. Identify at least one non-pharmaceutical method they can practically implement to manage post-operative pain and reduce post-operative opioid prescribing.

2. Discuss multi-modal pain control and identify at least two non-opioid medications which can be used to manage post-operative pain and reduce post-operative opioid prescribing.

Difficult Cases in High-Risk Bladder Cancer: An Evidence-Based Approach (2022)

CME Available: https://auau.auanet.org/node/36020

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Identify low, intermediate and high risk non-muscle invasive bladder cancer (NMIBC)

2. Recommend treatment for NMIBC based on risk stratification.

3. Identify bacillus Calmette-Guérin (BCG) unresponsive NMIBC and novel immune-based strategies and intravesical therapies.

4. Manage invasive bladder cancer including surgery, neoadjuvant and adjuvant chemotherapy and bladder preservation strategies in patients with muscle invasive bladder cancer. This will include chemotherapy indications and the role of immunotherapy in the management.

5. Manage upper tract tumors, both low grade and high grade, including renal preservation when appropriate, neoadjuvant therapy when indicated and surgical management strategies.

The Changing Face of Advanced Prostate Cancer 2022(2022)

CME Available: https://auau.auanet.org/node/36010

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Identify and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be able to offer additional therapies that extend survival.

2. Recognize high volume new M1 prostate cancer to be able to refer to a genitourinary (GU) medical oncologist for systemic chemotherapy.

3. Diagnose M0 metastatic CRPC and educate patients about using novel oral AR targeted therapeutics added to traditional ADT as a way to improve their patient's overall and radiographic progression-free survival.

4. Identify the differences between these AR targeted oral agents and to educate patients about side effects and toxicities.

5. Describe the latest phase III randomized control trial (RCT) results for new therapies in M1 CRPC.

Host: Jay D. Raman, MD, FACS

Guest: Akanksha Mehta, MD, MS

For more information or to subscribe to the AUA Update Series, please visit: AUAnet.org/University

Diversity Equity and Inclusion in Urology: What Do We Need to Know?

CME Available: https://auau.auanet.org/node/35746

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

1. Identify the different forms of racism and, more importantly, identify their own subconscious personal bias.

2. Identify the impact of race on medical education, research and clinical care.

3. Identify how DEI initiatives can positively impact the practice of urology.

4. Examine innovative methodologies employed to increase the numbers of underrepresented groups in urology.

5. Participate in activities to encourage and support individualism among urology team members.

Should I Order a PET Scan? Integrating Molecular Imaging Into Urologic Oncology Clinical Practice: Current Approaches and Future Opportunities

CME Available: https://auau.auanet.org/node/36003

LEARNING OBJECTIVES

At the conclusion of this course, participants will be able to:

1. Analyze the best available evidence on the current diagnostic imaging options for prostate, kidney and urothelial cancer detection, staging and follow-up.

2. Determine the benefits of combined functional and anatomical information gained through accurate matching of anatomical (CT/MRI) and functional (PET) images.

3. Debate the strengths and limitations of emerging molecular imaging techniques compared to existing diagnostic tests.

4. Utilize performance characteristics of standard and emerging molecular imaging modalities to stage urologic oncology patients.

5. Describe the emerging role of PET imaging and novel radiotracers to assess chemotherapy and immunotherapy response.

CME Available: https://auau.auanet.org/node/35793

Course Director: Amy Krambeck, MD

Faculty: Dean Elterman, MD; Steven Kaplan, MD; Lori Lerner, MD

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

Cook Medical

Olympus Corporation of the Americas

LEARNING OBJECTIVES

At the conclusion of the activity, participants will be able to:

1. Identify the role of diagnostic testing in making the accurate diagnosis of mLUTS using the new benign BPH guidelines.

2. Recognize the various agents available to treat mLUTS.

3. Describe the indications for the various ablative BPH procedures.

4. Illustrate the impact of current therapeutic strategies on both voiding and sexual dysfunction.

5. Identify the role of the AUA guidelines for BPH for the surgical and medical management of BPH.

CME Available: https://auau.auanet.org/node/35710

Course Director: Stephen A. Boorjian, MD

Faculty: Leonard G. Gomella, MD, FACS; David F. Jarrard, MD; Alicia K. Morgans, MD, MPH

ACKNOWLEDGMENTS:

This educational activity is supported by independent education grants from:

Astellas

AstraZeneca

Merck & Co., Inc.

Pfizer, Inc.

At the conclusion of the activity, participants will be able to:

LEARNING OBJECTIVES:

1. Describe recent developments in the medical management of advanced prostate cancer.

Identify the active agents and their mechanism of action in the management of mHSPC, nmCRPC and mCRPC.

2. Discuss clinical investigations in the treatment of advanced prostate cancer.

3. Analyze the risks and benefits of treatment for advanced prostate cancer.

4. Identify the criteria for genetic and genomic testing and utilize the results to improve outcomes among patients with advanced prostate cancer.

CME Available: https://auau.auanet.org/node/35599

Course Director: David A. Ginsberg, MD

Faculty: Anne P. Cameron, MD, FRCSC, FPMRS; Sara M. Lenherr, MD, MS, FPRMS, Eric Rovner, MD; Eric Rovner, MD

ACKNOWLEDGEMENTS

This educational activity is supported by an independent educational grant from:

Urovant

LEARNING OBJECTIVES

At the conclusion of the activity, participants will be able to:

1. Define the similarities and differences between the various oral pharmacotherapies for OAB and discuss the potential future pharmacological pathways and therapies.

2. Describe the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.

3. Discuss optimal use of third line therapies in order to maximize clinical benefit.

4. Counsel patients on the pros and cons and risks and benefits of each of the third line therapies for OAB.

Publishing Ethics

Co-Host: John P. Mulhall, MD

Outline:

Segment 1: The 4 R's of scientific publishing

Segment 2: Plagiarism

Segment 3: Authorship issues

Segment 4: Conflict of interest

Segment 5: IRB (IACUC) issues

Segment 6: Fabrication/Falsification

Segment 7: Reviewer malpractice

Segment 8: Predatory journals